Dual antiplatelet therapy post-percutaneous coronary intervention in cardiovascular patients Comparative analysis with previous generation PPI drugs "P-CAB class K-CAB reduces gastrointestinal bleeding risk"
HK Inno.N K-CAB
Research has shown that HK Inno.N's new drug for gastroesophageal reflux disease, 'K-CAB (active ingredient: Tegoprazan)', may also be effective in treating patients with cardiovascular disease.
On the 10th, HK Inno.N announced the results of a study that administered K-CAB to patients with cardiovascular disease and compared it with previous generation gastroesophageal reflux disease treatments, specifically the PPI class of drugs.
This study, led by a research team from Yonsei University College of Medicine at Yongin Severance Hospital, was conducted on patients with acute myocardial infarction treated with dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI). DAPT is a treatment aimed at reducing ischemic events in cardiovascular disease patients post-PCI. However, it is known to increase the risk of gastrointestinal bleeding. To prevent this, PPI class drugs for gastroesophageal reflux disease are widely used, although concerns about drug interactions with antiplatelet agents have been continuously raised.
Amidst this, the Yonsei University research team focused on the P-CAB class drug K-CAB, which is characterized by rapid onset, long duration, and low drug interaction. The study was conducted to explore its potential as a replacement for PPI products. Specifically, using nationwide big data from the Health Insurance Review and Assessment Service, the study compared and analyzed patients in Korea who received PCI for acute myocardial infarction (AMI) and were taking either PPI class drugs (19,201 patients) or Tegoprazan (P-CAB class, 2,075 patients) alongside DAPT. The baseline characteristics of the two patient groups were statistically adjusted, and the main evaluation indicators were set as gastrointestinal bleeding within one year and major adverse cardiac and cerebrovascular events (MACCE), including myocardial infarction and stroke.
The study found that the risk of gastrointestinal bleeding within one year was approximately 28% lower in the K-CAB group compared to the PPI group. It was confirmed that the risk of major adverse cardiac and cerebrovascular events, such as myocardial infarction or stroke, did not increase.
An HK Inno.N representative said, "Through this study, we expect that K-CAB can provide differentiated clinical value in the field of cardiovascular patient treatment."
Meanwhile, the study results were presented as a poster at the European Society of Cardiology (ESC 2025) held in Madrid, Spain, last month.
Kim Min-beom
AI-translated with ChatGPT. Provided as is; original Korean text prevails.
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
About Dong-A Ilbo